Jennifer Pfahler - Cue Health Independent Director
| HLTH Stock | USD 0.14 0.01 6.67% |
Director
Ms. Jennifer Pfahler is an independent director of Nobilis Health Corporationration . Ms. Pfahler is a consumer health, wellness and lifestyle specialist and has worked with leading national brands, hospitals, and public health organizations for over 22 years. She actively represents leading health, foodnutrition and consumer product and technology companies including Merck Consumer Healthcare, Glaxo SmithKline, Pfizer, Johnson Johnson, The Dannon Company, GNC, Microsoft, SpaFinder Welnness, and the American Heart Association. Ms. Pfaller is also on the faculty at New York University in the School of Continuing and Professional Studies and a board member of the American Diabetes Association NY Chapter, and on the American Heart Association Consumer Health board committee since 2012.
| Age | 45 |
| Tenure | 12 years |
| Address | 4980 Carroll Canyon Road, San Diego, CA, United States, 92121 |
| Phone | 858 412 8151 |
| Web | https://www.cuehealth.com |
Cue Health Management Efficiency
The company has return on total asset (ROA) of (0.3188) % which means that it has lost $0.3188 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9035) %, meaning that it created substantial loss on money invested by shareholders. Cue Health's management efficiency ratios could be used to measure how well Cue Health manages its routine affairs as well as how well it operates its assets and liabilities. The Cue Health's current Return On Tangible Assets is estimated to increase to -1.11. The current Return On Capital Employed is estimated to decrease to -1.05. As of now, Cue Health's Intangibles To Total Assets are increasing as compared to previous years. The Cue Health's current Fixed Asset Turnover is estimated to increase to 0.86, while Non Current Assets Total are projected to decrease to under 212.8 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Heidi Kunz | Agilent Technologies | 66 | |
| Nancy Andrews | Charles River Laboratories | 63 | |
| Hans Bishop | Agilent Technologies | 56 | |
| David Walt | Illumina | 62 | |
| Robert Epstein | Illumina | 62 | |
| Joshua Bekenstein | Waters | 56 | |
| Hans Maerki | Mettler Toledo International | 71 | |
| Robert Herbold | Agilent Technologies | 74 | |
| Debora Spar | Thermo Fisher Scientific | 56 | |
| Dion Weisler | Thermo Fisher Scientific | 53 | |
| Constance Harvey | Mettler Toledo International | 56 | |
| Arthur Bowman | Illumina | 69 | |
| John Thompson | Illumina | 68 | |
| Elaine Ullian | Thermo Fisher Scientific | 70 | |
| Dipchand Nishar | Guardant Health | N/A | |
| Stephen Chubb | Charles River Laboratories | 76 | |
| Deborah Kochevar | Charles River Laboratories | 64 | |
| Virginia Wilson | Charles River Laboratories | 66 | |
| Karin Eastham | Illumina | 67 | |
| Stanley Meresman | Guardant Health | 71 | |
| Linda Baddour | Waters | 62 | |
Management Performance
| Return On Equity | -0.9 | ||||
| Return On Asset | -0.32 |
Cue Health Leadership Team
Elected by the shareholders, the Cue Health's board of directors comprises two types of representatives: Cue Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cue. The board's role is to monitor Cue Health's management team and ensure that shareholders' interests are well served. Cue Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cue Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Steve Ozonian, Chairman of the Board | ||
| Harry Fleming, CEO, Director, Chairman of Acquisition Committee and Chairman of Strategy Committee | ||
| Phil Ayres, Chief Marketing Officer | ||
| Nitin Duggal, Chief Officer | ||
| Thomas Foster, Director | ||
| James Springfield, CEO | ||
| John Gallagher, Chief Officer | ||
| Marcos Rodriguez, Chief Accounting Officer | ||
| Kenneth Efird, President | ||
| Clint Sever, CoFounder Officer | ||
| Donald Kramer, Director | ||
| Randall Pollard, Controller Officer | ||
| Christopher Achar, Chief Director | ||
| Suzanne Stone, Chief Officer | ||
| Erica Esq, General Secretary | ||
| Lorna Williams, Vice Relations | ||
| Kenneth Klein, CFO | ||
| Allison Blackwell, Chief Officer | ||
| David Arida, Chief Officer | ||
| Ayub Khattak, President, CoFounder | ||
| Brandon Moreno, CFO | ||
| Kenny Klein, CFO, Chief Accounting Officer | ||
| Dena Cook, Chief Officer | ||
| Jennifer Pfahler, Independent Director | ||
| David Young, CFO | ||
| Aasim Javed, Treasurer CFO | ||
| Richard Ganley, Independent Director | ||
| Eileen Sheil, Chief Officer | ||
| Michael Nichols, Director | ||
| Susan Watt, Director | ||
| Neil Badlani, Director | ||
| Steven Ozonian, Chairman of the Board | ||
| David MD, Chief Officer |
Cue Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cue Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.9 | ||||
| Return On Asset | -0.32 | ||||
| Operating Margin | (2.83) % | ||||
| Current Valuation | (10.44 M) | ||||
| Shares Outstanding | 158.52 M | ||||
| Shares Owned By Insiders | 12.82 % | ||||
| Shares Owned By Institutions | 47.86 % | ||||
| Number Of Shares Shorted | 563.52 K | ||||
| Price To Earning | 16.86 X | ||||
| Price To Book | 0.10 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Cue Health. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Cue Stock please use our How to Invest in Cue Health guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Complementary Tools for Cue Stock analysis
When running Cue Health's price analysis, check to measure Cue Health's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cue Health is operating at the current time. Most of Cue Health's value examination focuses on studying past and present price action to predict the probability of Cue Health's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cue Health's price. Additionally, you may evaluate how the addition of Cue Health to your portfolios can decrease your overall portfolio volatility.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |
Is Cue Health's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cue Health. If investors know Cue will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cue Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.77) | Earnings Share (2.44) | Revenue Per Share 0.464 | Quarterly Revenue Growth (0.87) | Return On Assets (0.32) |
The market value of Cue Health is measured differently than its book value, which is the value of Cue that is recorded on the company's balance sheet. Investors also form their own opinion of Cue Health's value that differs from its market value or its book value, called intrinsic value, which is Cue Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cue Health's market value can be influenced by many factors that don't directly affect Cue Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cue Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cue Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cue Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.